MRK
Merck & Co., Inc.
$128.86
+2.08 (+1.64%)
At close · Jul 7
Market Cap
$311.17B
Shares
2,469,824,415
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$65.01B
+1.3%
FY2025
Net Income
$18.25B
+6.6%
FY2025
Gross Margin
74.8%
-1.5pp
FY2025
Diluted EPS
$7.28
+8%
FY2025
Operating Cash Flow
$16.47B
-23.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $65.8B – $67B | $65.77B | $65.01B | $64.17B | $60.12B | $59.28B | $48.7B | $47.99B | $46.84B | $42.29B | — | — | — | — | — | — | — | $45.99B | $27.43B | |
| — | $17.16B | $16.38B | $15.19B | $16.13B | $17.41B | $13.63B | $15.49B | $14.11B | $13.51B | $12.78B | $13.89B | $14.93B | $16.77B | $16.95B | $16.45B | $16.87B | $18.4B | $9.02B | |
| — | $48.61B | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B | $32.51B | $32.73B | $28.79B | — | — | — | — | — | — | — | $27.59B | $18.41B | |
| — | — | 74.8% | 76.32% | 73.17% | 70.63% | 72.02% | 67.74% | 69.87% | 68.06% | — | — | — | — | — | — | — | 60% | 67.12% | |
| — | $24.76B | $15.79B | $17.94B | $30.53B | $13.55B | $12.25B | $13.56B | $9.87B | $9.75B | $10.21B | $10.12B | $6.7B | $7.18B | $7.5B | $8.17B | $8.47B | $10.99B | $5.85B | |
| — | $10.88B | $10.73B | $10.82B | $10.5B | $10.04B | $9.63B | $10.47B | $10.62B | $10.1B | $9.83B | $9.76B | $10.31B | $11.61B | $11.91B | $12.78B | $13.73B | $13.25B | $8.54B | |
| — | — | $2.8B | $2.4B | $2B | $2.1B | $1.6B | $1.9B | $2B | $2.9B | $3.2B | $3.8B | $4.8B | $4.2B | $4.8B | $5B | — | — | — | |
| — | — | — | — | — | — | — | — | $3.65B | $4.52B | $4.64B | $5.44B | $6.38B | $6.69B | $6.99B | $6.98B | $7.43B | $7.38B | $2.58B | |
| — | $1.02B | $889M | $309M | $599M | $337M | $661M | $578M | $638M | $632M | $776M | $651M | $619M | $1.01B | $1.71B | $664M | $1.31B | $985M | $1.63B | |
| — | $1.52B | $1.36B | $1.27B | $1.15B | $962M | $806M | $831M | $893M | $772M | $754M | $693M | $672M | $732M | $801M | $714M | $749M | $715M | — | |
| — | $269M | $343M | $415M | $365M | $157M | $36M | $59M | $274M | $343M | $385M | $328M | $289M | $266M | $264M | $232M | $199M | $83M | — | |
| — | -$324M | -$151M | $24M | -$466M | -$1.5B | $1.34B | $886M | -$139M | $402M | -$12M | -$720M | -$1.53B | $11.36B | -$815M | -$1.12B | -$946M | -$1.3B | $10.67B | |
| — | $125M | — | — | — | — | — | — | — | — | $42M | $86M | $205M | $257M | $404M | $642M | $610M | $587M | $2.24B | |
| — | $11.63B | $21.07B | $19.94B | $1.89B | $16.44B | $13.88B | $8.79B | $11.46B | $8.7B | $6.52B | $4.66B | $5.4B | $17.28B | $5.55B | $8.74B | $7.33B | — | — | |
| — | $2.7B | $2.8B | $2.8B | $1.51B | $1.92B | $1.52B | $1.71B | $1.69B | $2.51B | $4.1B | $718M | $942M | $5.35B | $1.03B | $2.44B | $942M | $671M | $2.27B | |
| — | $8.94B | $18.25B | $17.12B | $365M | $14.52B | $13.05B | $7.07B | $9.84B | $6.22B | $2.39B | $3.92B | $4.44B | $11.92B | $4.4B | $6.17B | $6.27B | $861M | $12.9B | |
| — | — | 28.08% | 26.68% | 0.61% | 24.49% | 26.79% | 14.72% | 21.01% | 14.71% | — | — | — | — | — | — | — | 1.87% | 47.04% | |
| — | $0 | $9M | $16M | $12M | $7M | $16M | $15M | -$66M | -$27M | $24M | $21M | $17M | $14M | $113M | $131M | $120M | $121M | $122.9M | |
| — | $8.94B | $18.25B | $17.12B | $365M | $14.52B | $13.05B | — | — | — | — | — | — | $11.92B | $4.4B | $6.17B | $6.26B | $859M | $12.9B | |
| — | $9.84B | $18.91B | $17.33B | -$28M | $14.18B | $14.81B | $6.63B | $9.2B | $5.86B | $2.71B | $2.84B | $4.62B | $9.79B | $6.89B | — | — | — | — | |
| USD/shares | — | — | $7.30 | $6.76 | $0.14 | $5.73 | $5.16 | $2.66 | $3.66 | $2.23 | $0.84 | $1.35 | $1.51 | $3.93 | $1.42 | $1.94 | $1.95 | $0.27 | $5.41 |
| USD/shares | $5.04 – $5.16* | — | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.65 | $3.64 | $2.21 | $0.83 | $1.35 | $1.49 | $3.88 | $1.40 | $1.91 | $1.93 | $0.27 | $5.39 |
| shares | — | — | 2.5B | 2.53B | 2.54B | 2.53B | 2.53B | 2.65B | 2.69B | 2.79B | 2.86B | 2.9B | 2.95B | 3.03B | 3.11B | 3186.968 | 3.22B | 3.24B | — |
| shares | — | — | 2.51B | 2.54B | 2.55B | 2.54B | 2.54B | 2.66B | 2.7B | 2.81B | 2.88B | 2.92B | 2.98B | 3.07B | 3.14B | 3223.648 | 3.24B | 3.27B | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $55.69B in buybacks, $97.66B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
35.49×
Drug Manufacturers - General median 23.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceuticalsegment | $58,142,000,000 | $57,400,000,000 | $53,583,000,000 | $52,005,000,000 | $42,754,000,000 | $36,610,000,000 | $34,100,000,000 | $37,689,000,000 |
| Animal Health Segment | $6,354,000,000 | $5,877,000,000 | $5,625,000,000 | $5,550,000,000 | $5,568,000,000 | $4,703,000,000 | $4,393,000,000 | $4,212,000,000 |
| All Other Segments | — | — | — | $0 | $0 | $23,000,000 | $175,000,000 | $250,000,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $36,362,000,000 | $32,151,000,000 | $28,343,000,000 | $26,811,000,000 | $22,159,000,000 | $19,517,000,000 | $18,334,000,000 | $18,228,000,000 |
| Non Us | $28,134,000,000 | $31,126,000,000 | $30,865,000,000 | — | — | — | — | — |
| EMEA | $14,580,000,000 | $14,041,000,000 | $13,254,000,000 | $14,493,000,000 | $13,341,000,000 | $11,547,000,000 | $10,496,000,000 | $12,213,000,000 |
| Latin America | $3,410,000,000 | $3,459,000,000 | $3,086,000,000 | $2,582,000,000 | $2,206,000,000 | $1,890,000,000 | $2,015,000,000 | $2,415,000,000 |
| Asia Pacific | $2,983,000,000 | $3,058,000,000 | $3,225,000,000 | $3,614,000,000 | $2,407,000,000 | $2,113,000,000 | $2,126,000,000 | $2,909,000,000 |
| Other Countries | $2,878,000,000 | $2,559,000,000 | $2,104,000,000 | $2,568,000,000 | $1,221,000,000 | $1,027,000,000 | $1,275,000,000 | $1,015,000,000 |
| Japan | $2,711,000,000 | $3,280,000,000 | $3,164,000,000 | $3,629,000,000 | $2,726,000,000 | $2,602,000,000 | $2,609,000,000 | $3,212,000,000 |
| China | $1,939,000,000 | $5,494,000,000 | $6,802,000,000 | $5,191,000,000 | $4,378,000,000 | $2,751,000,000 | $2,180,000,000 | $2,184,000,000 |
| International | — | $31,126,000,000 | $30,865,000,000 | $30,744,000,000 | $26,163,000,000 | $21,819,000,000 | $20,333,000,000 | $23,923,000,000 |
Key facts
CIK
310158
CUSIP
58933Y105
13F (30d)
252 filings
173 filers
Visit website
Investor relations